BXRX
- Baudax Bio, Inc.
()
Overview
Company Summary
Baudax Bio, Inc. (BXRX) is a pharmaceutical company that specializes in developing and commercializing innovative products for acute care settings. Formerly known as Recro Pharma, the company changed its name to Baudax Bio in 2019 to align with its focus on a new product line.
BXRX primarily focuses on developing non-opioid therapeutics for the management of pain. The company's flagship product is ANJESO�, a non-opioid intravenous analgesic used for the management of moderate to severe pain. ANJESO� is designed to provide extended pain relief while minimizing potential opioid-related adverse effects.
In addition to ANJESO�, Baudax Bio also aims to develop and commercialize other non-opioid pain management products. The company recognizes the need for alternative options to address pain control in acute care, particularly in post-operative settings. Their mission is to improve patient outcomes by reducing reliance on opioids and introducing innovative solutions for pain management.
Baudax Bio focuses on conducting clinical trials to demonstrate the safety and efficacy of their products. They collaborate with healthcare professionals, payers, and key opinion leaders in the medical field to ensure their products meet the needs of patients and healthcare providers. The company's strategic approach includes pursuing regulatory approvals, building strategic partnerships, and establishing a strong market presence to bring their products to healthcare settings worldwide.
Overall, Baudax Bio aims to revolutionize pain management in acute care settings by providing safer and effective alternatives to opioid-based medications.